Afya Ltd
F:1AY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Afya Ltd
F:1AY
|
BR |
|
H
|
Hess Corp
XBER:AHC
|
US |
|
B
|
Biomarin Pharmaceutical Inc
SWB:BM8
|
US |
|
C
|
Cigna Corp
XHAM:CGN
|
US |
|
Palo Alto Networks Inc
BMV:PANW
|
US |
|
W
|
Westport Fuel Systems Inc
XBER:WPIA
|
CA |
|
MatsukiyoCocokara & Co
TSE:3088
|
JP |
|
Hudbay Minerals Inc
TSX:HBM
|
CA |
|
Samsung Electronics Co Ltd
KRX:005930
|
KR |
|
M
|
MTU Aero Engines AG
XBER:MTX
|
DE |
|
Renault SA
PAR:RNO
|
FR |
|
U
|
Unicharm Corp
XBER:UN4
|
JP |
|
M&T Bank Corp
F:MTZ
|
US |
|
Engie SA
F:GZFB
|
FR |
|
R
|
RH
XBER:RS1
|
US |
|
MFE-MEDIAFOREUROPE NV
MAD:MFEA
|
IT |
|
Chimera Investment Corp
LSE:0A7B
|
US |
|
Colony Bankcorp Inc
NYSE:CBAN
|
US |
|
S
|
Sumitomo Chemical Co Ltd
F:SMM
|
JP |
|
Zhejiang Sling Intelligent Drive Group Co Ltd
SZSE:301550
|
CN |
|
PT Dayamitra Telekomunikasi Tbk
IDX:MTEL
|
ID |
|
Annaly Capital Management Inc
F:AAYA
|
US |
|
Q
|
Qiagen NV
LSE:0RLT
|
NL |
|
S
|
Schumag AG
XHAM:SCM
|
DE |
Afya Ltd
Afya Ltd is a medical education company in Brazil. It runs medical schools and other education programs for people training to become doctors, and it also offers continuing education and digital learning tools for physicians. Its core business is preparing and supporting medical professionals across their careers, from student training to ongoing professional development. The company makes money mainly by charging tuition and related education fees. It also earns from subscriptions and services tied to digital content, test preparation, and professional education. Its customers are mostly medical students, doctors, and other healthcare professionals, along with institutions that use its training and education products. What makes Afya different is that it sits at the intersection of education and healthcare. Instead of selling to hospitals or patients, it sells specialized training and learning services to the medical community. That gives it a focused role in the supply chain for new doctors and in the ongoing education market for practicing clinicians.
Afya Ltd is a medical education company in Brazil. It runs medical schools and other education programs for people training to become doctors, and it also offers continuing education and digital learning tools for physicians. Its core business is preparing and supporting medical professionals across their careers, from student training to ongoing professional development.
The company makes money mainly by charging tuition and related education fees. It also earns from subscriptions and services tied to digital content, test preparation, and professional education. Its customers are mostly medical students, doctors, and other healthcare professionals, along with institutions that use its training and education products.
What makes Afya different is that it sits at the intersection of education and healthcare. Instead of selling to hospitals or patients, it sells specialized training and learning services to the medical community. That gives it a focused role in the supply chain for new doctors and in the ongoing education market for practicing clinicians.
Top line: Afya said revenue rose 8% year over year to BRL 1.013 billion, with adjusted EBITDA up 4% to BRL 511 million and adjusted EBITDA margin at 50.5%.
Cash generation: Free cash flow came in at BRL 376 million, cash conversion was 92.5%, and the company ended the quarter with BRL 1.3 billion in cash.
Undergrad strength: Management highlighted a strong intake cycle, higher medicine ticket prices, and growth in nonmedical health programs as key drivers of the quarter.
Segment mix: Continuing education and Medical Practice Solutions both grew, but the company said more investment is still being made in these businesses, which weighed on margins.
WhiteBook/AI: Afya is pushing WhiteBook toward an AI-first, more integrated platform and said the revenue impact from this year’s investments should be limited until 2027 and beyond.
Guidance discipline: Management said the ENAMED-related second-half impact is already included in guidance and described sales and marketing spending as embedded in the full-year outlook.
